In Vivo Quantitative Photoacoustic Diagnosis of Gastric and Intestinal Dysfunctions with a Broad pH-Responsive Sensor Wenchao Huang State Key Laboratory of Molecular Vaccinology and Molecular ...

New treatment approaches are expanding the ways gastric cancer can be managed, with a focus on quality of life. Photos: Shutterstock, Icon Cancer Centre. New: You can now listen to articles.

Background and aim: Gastric intestinal metaplasia (IM) is generally considered to be a precancerous lesion in the gastric carcinogenesis cascade. This study identified the risk factors associated with ...

Abstract: Metaplasia, growth of normal tissue in an abnormal location, is a precursor lesion of gastric cancer (GC). Despite the huge impact of the Operative Link on Gastritis Assessment based on ...

ABSTRACT. Background: There is no consensus on the ideal size of intestinal loops in gastric bypass of bariatric surgeries. Aim: To evaluate the metabolic outcome of patients submitted to gastric ...

A Case Report of Monomorphic Epithelial Intestinal T-Cell Lymphoma and Literature Review Jing Deng, Yongguang Zou, Guangshu Li International Journal of Clinical Medicine Vol.11 No.2 , February 12, ...

Changes in the microbiota are accompanied by an increase in gastric leptin, leading to the development of intestinal metaplasia (Arita and Inagaki-Ohara, 2019; Arita et al., 2019). Typically, ...

Trastuzumab deruxtecan (T-DXd) improved survival outcomes when compared to ramucirumab and paclitaxel as second-line treatment in a phase 3 trial of patients with HER2-positive, metastatic gastric ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen ...

Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca) and chemotherapy both before and after surgery ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...